| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Typhoid Fever | 12 | 2019 | 139 | 4.80 | Why? |
| Salmonella typhi | 9 | 2019 | 98 | 3.42 | Why? |
| Typhoid-Paratyphoid Vaccines | 7 | 2019 | 34 | 3.40 | Why? |
| Antibodies, Bacterial | 16 | 2019 | 510 | 3.40 | Why? |
| Pneumococcal Vaccines | 9 | 2019 | 571 | 2.93 | Why? |
| Meningococcal Vaccines | 9 | 2018 | 225 | 2.79 | Why? |
| Immunization, Secondary | 11 | 2021 | 1649 | 2.15 | Why? |
| Vaccines, Conjugate | 9 | 2019 | 328 | 2.13 | Why? |
| Meningococcal Infections | 5 | 2018 | 216 | 2.12 | Why? |
| Streptococcus pneumoniae | 7 | 2019 | 827 | 2.09 | Why? |
| Tetanus Toxoid | 3 | 2018 | 136 | 1.88 | Why? |
| Immunization Schedule | 5 | 2021 | 1305 | 1.49 | Why? |
| Meningitis, Meningococcal | 3 | 2018 | 114 | 1.42 | Why? |
| Neisseria meningitidis | 3 | 2018 | 229 | 1.33 | Why? |
| Pneumococcal Infections | 5 | 2019 | 562 | 1.17 | Why? |
| Global Burden of Disease | 2 | 2019 | 531 | 1.14 | Why? |
| Carrier State | 5 | 2021 | 2100 | 1.07 | Why? |
| Respiratory Syncytial Virus, Human | 3 | 2019 | 846 | 1.03 | Why? |
| Polysaccharides, Bacterial | 3 | 2018 | 59 | 0.95 | Why? |
| Respiratory Syncytial Virus Vaccines | 2 | 2019 | 104 | 0.87 | Why? |
| Respiratory Syncytial Virus Infections | 3 | 2019 | 1234 | 0.86 | Why? |
| Immunologic Memory | 4 | 2021 | 3362 | 0.86 | Why? |
| Paratyphoid Fever | 2 | 2017 | 19 | 0.86 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2018 | 64 | 0.83 | Why? |
| Drug Resistance, Bacterial | 3 | 2018 | 1414 | 0.82 | Why? |
| Encephalitis | 3 | 2019 | 797 | 0.80 | Why? |
| B-Lymphocytes | 4 | 2019 | 4418 | 0.76 | Why? |
| Salmonella paratyphi A | 2 | 2017 | 22 | 0.74 | Why? |
| Immunogenicity, Vaccine | 9 | 2021 | 4624 | 0.73 | Why? |
| Neisseria meningitidis, Serogroup Y | 1 | 2017 | 4 | 0.72 | Why? |
| Immunosenescence | 1 | 2020 | 169 | 0.71 | Why? |
| Neisseria meningitidis, Serogroup B | 2 | 2017 | 66 | 0.70 | Why? |
| Glycoconjugates | 1 | 2017 | 32 | 0.69 | Why? |
| Powders | 1 | 2017 | 121 | 0.68 | Why? |
| Vaccines | 5 | 2021 | 3692 | 0.68 | Why? |
| Neisseria meningitidis, Serogroup C | 1 | 2016 | 46 | 0.65 | Why? |
| Haemophilus Vaccines | 1 | 2016 | 76 | 0.64 | Why? |
| Immunity, Heterologous | 1 | 2017 | 129 | 0.64 | Why? |
| Infant | 29 | 2019 | 30274 | 0.64 | Why? |
| Bacteremia | 2 | 2017 | 1372 | 0.61 | Why? |
| Encephalitis, Viral | 2 | 2017 | 355 | 0.58 | Why? |
| Cytomegalovirus | 1 | 2020 | 600 | 0.57 | Why? |
| Vaccination | 19 | 2021 | 19050 | 0.56 | Why? |
| Nepal | 6 | 2019 | 1004 | 0.56 | Why? |
| Blood Culture | 1 | 2017 | 308 | 0.55 | Why? |
| Cytomegalovirus Infections | 1 | 2020 | 667 | 0.52 | Why? |
| Healthy Volunteers | 5 | 2020 | 1444 | 0.51 | Why? |
| Drug Carriers | 1 | 2019 | 590 | 0.49 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.48 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.47 | Why? |
| Intensive Care Units, Pediatric | 1 | 2019 | 1098 | 0.47 | Why? |
| Body Temperature | 1 | 2017 | 875 | 0.46 | Why? |
| Child, Preschool | 23 | 2019 | 36283 | 0.44 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.43 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.43 | Why? |
| Respiratory Mucosa | 1 | 2019 | 1522 | 0.41 | Why? |
| Pain | 1 | 2018 | 1084 | 0.40 | Why? |
| Central Nervous System Infections | 1 | 2011 | 158 | 0.38 | Why? |
| Serogroup | 4 | 2019 | 510 | 0.38 | Why? |
| Single-Blind Method | 6 | 2021 | 1283 | 0.36 | Why? |
| Anti-Bacterial Agents | 4 | 2018 | 10083 | 0.36 | Why? |
| Anti-Infective Agents | 2 | 2018 | 1766 | 0.36 | Why? |
| Opsonin Proteins | 2 | 2017 | 18 | 0.35 | Why? |
| Blood Bactericidal Activity | 2 | 2017 | 19 | 0.35 | Why? |
| Bronchiolitis, Viral | 2 | 2018 | 71 | 0.35 | Why? |
| Immunity, Cellular | 2 | 2020 | 3614 | 0.32 | Why? |
| Antigens, Bacterial | 3 | 2018 | 330 | 0.31 | Why? |
| Immunocompromised Host | 2 | 2018 | 5150 | 0.31 | Why? |
| Enzyme-Linked Immunospot Assay | 2 | 2017 | 325 | 0.31 | Why? |
| Adolescent | 27 | 2021 | 86841 | 0.30 | Why? |
| Humans | 83 | 2021 | 930598 | 0.30 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.29 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.29 | Why? |
| T-Lymphocytes | 7 | 2021 | 6670 | 0.29 | Why? |
| Immunity, Humoral | 2 | 2020 | 4849 | 0.29 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.28 | Why? |
| Immunization Programs | 5 | 2021 | 2006 | 0.27 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.27 | Why? |
| Immunoglobulin G | 11 | 2021 | 21571 | 0.26 | Why? |
| Urban Population | 1 | 2014 | 2000 | 0.26 | Why? |
| Immunologic Deficiency Syndromes | 2 | 2018 | 368 | 0.26 | Why? |
| Antibody Formation | 4 | 2021 | 4038 | 0.25 | Why? |
| Child | 17 | 2021 | 70012 | 0.25 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.24 | Why? |
| Mycobacterium bovis | 1 | 2004 | 125 | 0.24 | Why? |
| Cicatrix | 1 | 2004 | 129 | 0.24 | Why? |
| Neutrophils | 1 | 2019 | 5476 | 0.24 | Why? |
| Infant, Newborn | 12 | 2019 | 23105 | 0.24 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.23 | Why? |
| Female | 40 | 2021 | 380317 | 0.23 | Why? |
| Antibodies, Neutralizing | 11 | 2021 | 25288 | 0.23 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.23 | Why? |
| Male | 37 | 2021 | 367725 | 0.22 | Why? |
| Rural Population | 1 | 2014 | 2408 | 0.22 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.22 | Why? |
| Persuasive Communication | 1 | 2021 | 78 | 0.21 | Why? |
| Smoking | 1 | 2014 | 3358 | 0.20 | Why? |
| Mastadenovirus | 1 | 2019 | 18 | 0.20 | Why? |
| Developed Countries | 2 | 2021 | 500 | 0.20 | Why? |
| Streptococcal Vaccines | 1 | 2019 | 31 | 0.20 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.19 | Why? |
| Streptococcus | 1 | 2019 | 76 | 0.19 | Why? |
| Receptors, Laminin | 1 | 2018 | 6 | 0.19 | Why? |
| Antibody-Producing Cells | 1 | 2019 | 66 | 0.19 | Why? |
| Virus Activation | 1 | 2004 | 480 | 0.19 | Why? |
| United Kingdom | 11 | 2021 | 18046 | 0.19 | Why? |
| Cell Degranulation | 1 | 2019 | 130 | 0.19 | Why? |
| Penetrance | 1 | 2018 | 121 | 0.19 | Why? |
| Cost-Benefit Analysis | 3 | 2019 | 2259 | 0.18 | Why? |
| Parechovirus | 1 | 2018 | 48 | 0.18 | Why? |
| Nasopharynx | 1 | 2018 | 10224 | 0.18 | Why? |
| Togo | 1 | 2018 | 95 | 0.18 | Why? |
| Serotyping | 2 | 2017 | 154 | 0.18 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 526 | 0.18 | Why? |
| Culture Media | 2 | 2018 | 366 | 0.18 | Why? |
| Ribosomal Proteins | 1 | 2018 | 94 | 0.18 | Why? |
| Exons | 1 | 2018 | 158 | 0.18 | Why? |
| Arthritis, Infectious | 1 | 2019 | 111 | 0.18 | Why? |
| RNA Splicing | 1 | 2018 | 119 | 0.17 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2018 | 72 | 0.17 | Why? |
| Measles-Mumps-Rubella Vaccine | 2 | 2018 | 282 | 0.17 | Why? |
| Osteomyelitis | 1 | 2019 | 131 | 0.17 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 92 | 0.17 | Why? |
| Drug Administration Routes | 1 | 2017 | 106 | 0.17 | Why? |
| Genes, Bacterial | 1 | 2018 | 207 | 0.17 | Why? |
| Meningitis, Viral | 1 | 2018 | 97 | 0.17 | Why? |
| Antibodies, Viral | 11 | 2021 | 51949 | 0.17 | Why? |
| Ciprofloxacin | 1 | 2018 | 130 | 0.17 | Why? |
| Encephalitis, Japanese | 1 | 2017 | 58 | 0.17 | Why? |
| Young Adult | 16 | 2021 | 93724 | 0.16 | Why? |
| Glasgow Coma Scale | 1 | 2017 | 249 | 0.16 | Why? |
| Administration, Cutaneous | 1 | 2017 | 229 | 0.16 | Why? |
| Prevalence | 7 | 2018 | 25773 | 0.16 | Why? |
| Microscopy, Electron, Scanning | 1 | 2017 | 221 | 0.16 | Why? |
| Fluoroquinolones | 1 | 2018 | 235 | 0.16 | Why? |
| Complement C3 | 1 | 2019 | 271 | 0.16 | Why? |
| Vaccinia virus | 1 | 2019 | 346 | 0.16 | Why? |
| Censuses | 1 | 2017 | 172 | 0.16 | Why? |
| Specimen Handling | 1 | 2014 | 6190 | 0.16 | Why? |
| Growth Disorders | 1 | 2017 | 91 | 0.16 | Why? |
| Wales | 1 | 2019 | 758 | 0.16 | Why? |
| Antibodies, Monoclonal | 5 | 2021 | 8041 | 0.16 | Why? |
| Injections, Intramuscular | 1 | 2019 | 800 | 0.15 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.15 | Why? |
| World Health Organization | 2 | 2019 | 4213 | 0.15 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.15 | Why? |
| Meningitis | 1 | 2018 | 163 | 0.15 | Why? |
| Seroepidemiologic Studies | 4 | 2020 | 10017 | 0.15 | Why? |
| Blood | 1 | 2017 | 274 | 0.15 | Why? |
| Kenya | 1 | 2019 | 887 | 0.15 | Why? |
| Antigens | 1 | 2018 | 267 | 0.15 | Why? |
| Immunity, Maternally-Acquired | 1 | 2017 | 179 | 0.15 | Why? |
| Genetic Diseases, Inborn | 1 | 2017 | 190 | 0.15 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.15 | Why? |
| Adult | 22 | 2021 | 244371 | 0.15 | Why? |
| Bias | 2 | 2018 | 1109 | 0.14 | Why? |
| Phagocytosis | 1 | 2017 | 409 | 0.14 | Why? |
| Asia | 2 | 2019 | 2399 | 0.14 | Why? |
| Bacteriological Techniques | 1 | 2017 | 239 | 0.14 | Why? |
| Viral Vaccines | 3 | 2020 | 7560 | 0.14 | Why? |
| Enterovirus | 1 | 2018 | 402 | 0.14 | Why? |
| Placebos | 1 | 2017 | 629 | 0.14 | Why? |
| Administration, Intranasal | 1 | 2019 | 1132 | 0.14 | Why? |
| Random Allocation | 1 | 2017 | 773 | 0.13 | Why? |
| Spleen | 1 | 2018 | 877 | 0.13 | Why? |
| DNA-Binding Proteins | 1 | 2017 | 469 | 0.13 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.13 | Why? |
| Protein Biosynthesis | 1 | 2018 | 653 | 0.13 | Why? |
| Data Accuracy | 1 | 2019 | 715 | 0.13 | Why? |
| Policy Making | 2 | 2021 | 829 | 0.13 | Why? |
| Disability Evaluation | 1 | 2017 | 671 | 0.13 | Why? |
| Enterovirus Infections | 1 | 2018 | 404 | 0.13 | Why? |
| Cost of Illness | 3 | 2019 | 1903 | 0.13 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1573 | 0.13 | Why? |
| BCG Vaccine | 1 | 2004 | 1137 | 0.13 | Why? |
| Clinical Trials as Topic | 4 | 2021 | 7330 | 0.13 | Why? |
| Neutropenia | 1 | 2017 | 388 | 0.13 | Why? |
| Africa | 2 | 2019 | 2986 | 0.13 | Why? |
| Metagenomics | 1 | 2019 | 823 | 0.12 | Why? |
| England | 3 | 2019 | 5116 | 0.12 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.12 | Why? |
| Time-to-Treatment | 2 | 2021 | 5883 | 0.12 | Why? |
| Age Factors | 5 | 2020 | 21039 | 0.12 | Why? |
| Particle Size | 1 | 2017 | 1052 | 0.12 | Why? |
| Population Surveillance | 3 | 2018 | 4967 | 0.12 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.11 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.11 | Why? |
| Diagnostic Techniques, Neurological | 1 | 2011 | 46 | 0.11 | Why? |
| Genotyping Techniques | 1 | 2014 | 360 | 0.11 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.11 | Why? |
| Immunity, Herd | 1 | 2019 | 1011 | 0.11 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.11 | Why? |
| Guideline Adherence | 3 | 2018 | 2309 | 0.11 | Why? |
| Asymptomatic Infections | 3 | 2021 | 7218 | 0.10 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.10 | Why? |
| European Union | 1 | 2014 | 565 | 0.10 | Why? |
| Fever | 2 | 2017 | 7795 | 0.10 | Why? |
| Health Communication | 1 | 2021 | 1120 | 0.10 | Why? |
| Lymphocyte Subsets | 1 | 2017 | 987 | 0.10 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.10 | Why? |
| Norway | 1 | 2014 | 1004 | 0.10 | Why? |
| Microbiota | 1 | 2019 | 1240 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.09 | Why? |
| CHO Cells | 2 | 2021 | 831 | 0.09 | Why? |
| Cricetulus | 2 | 2021 | 936 | 0.09 | Why? |
| Incidence | 4 | 2019 | 25622 | 0.09 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 7868 | 0.09 | Why? |
| Proteomics | 1 | 2019 | 2481 | 0.09 | Why? |
| Global Health | 4 | 2021 | 13911 | 0.09 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.08 | Why? |
| Bangladesh | 3 | 2018 | 1620 | 0.08 | Why? |
| Hepatitis B Antibodies | 1 | 2008 | 142 | 0.08 | Why? |
| HEK293 Cells | 4 | 2021 | 8394 | 0.08 | Why? |
| Temperature | 1 | 2017 | 2305 | 0.08 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.08 | Why? |
| Sweden | 1 | 2014 | 1969 | 0.08 | Why? |
| Mothers | 1 | 2017 | 1624 | 0.08 | Why? |
| Research Design | 2 | 2020 | 5830 | 0.08 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.08 | Why? |
| Denmark | 1 | 2014 | 2654 | 0.08 | Why? |
| Spike Glycoprotein, Coronavirus | 6 | 2021 | 37182 | 0.08 | Why? |
| Vaccines, Synthetic | 1 | 2019 | 3231 | 0.08 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.08 | Why? |
| Hepatitis B Vaccines | 1 | 2008 | 245 | 0.08 | Why? |
| Lymphocytes | 1 | 2018 | 3056 | 0.07 | Why? |
| Double-Blind Method | 3 | 2021 | 5988 | 0.07 | Why? |
| HIV Infections | 2 | 2021 | 11620 | 0.07 | Why? |
| Aged | 8 | 2021 | 215776 | 0.07 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.07 | Why? |
| Mutation | 3 | 2021 | 12376 | 0.07 | Why? |
| Netherlands | 1 | 2014 | 3533 | 0.07 | Why? |
| Animals | 8 | 2021 | 78931 | 0.07 | Why? |
| Vero Cells | 4 | 2021 | 14117 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.07 | Why? |
| Mice | 3 | 2021 | 21357 | 0.07 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.07 | Why? |
| Health Resources | 1 | 2017 | 2592 | 0.07 | Why? |
| Models, Theoretical | 2 | 2019 | 6659 | 0.06 | Why? |
| Genetic Vectors | 2 | 2020 | 1600 | 0.06 | Why? |
| Feces | 1 | 2017 | 4235 | 0.06 | Why? |
| Uncertainty | 1 | 2014 | 1888 | 0.06 | Why? |
| Length of Stay | 2 | 2018 | 11042 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Neutralization Tests | 3 | 2021 | 6698 | 0.06 | Why? |
| Hospitals | 2 | 2018 | 11793 | 0.06 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.06 | Why? |
| Remuneration | 1 | 2020 | 19 | 0.06 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.05 | Why? |
| Adenoviruses, Simian | 1 | 2020 | 52 | 0.05 | Why? |
| Interferon-gamma | 2 | 2021 | 2711 | 0.05 | Why? |
| South Africa | 2 | 2021 | 3326 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Protein Binding | 3 | 2021 | 11430 | 0.05 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.05 | Why? |
| Retrospective Studies | 5 | 2019 | 105322 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Dose-Response Relationship, Drug | 2 | 2020 | 3776 | 0.05 | Why? |
| Hepatitis B | 1 | 2008 | 888 | 0.05 | Why? |
| Binding Sites, Antibody | 1 | 2021 | 466 | 0.05 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.05 | Why? |
| Vaccine Potency | 1 | 2021 | 339 | 0.05 | Why? |
| Practice Guidelines as Topic | 3 | 2018 | 15421 | 0.05 | Why? |
| Antigen-Antibody Complex | 1 | 2021 | 408 | 0.05 | Why? |
| Analgesics, Non-Narcotic | 1 | 2020 | 164 | 0.05 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2020 | 593 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Epitopes | 2 | 2021 | 4113 | 0.05 | Why? |
| Founder Effect | 1 | 2018 | 92 | 0.05 | Why? |
| Longitudinal Studies | 1 | 2014 | 9893 | 0.04 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.04 | Why? |
| Vaccines, Combined | 1 | 2018 | 67 | 0.04 | Why? |
| Carrier Proteins | 1 | 2021 | 513 | 0.04 | Why? |
| Streptococcus agalactiae | 1 | 2019 | 194 | 0.04 | Why? |
| Protein Subunits | 1 | 2020 | 755 | 0.04 | Why? |
| Tetanus | 1 | 2018 | 61 | 0.04 | Why? |
| Spinal Puncture | 1 | 2018 | 95 | 0.04 | Why? |
| Heterozygote | 1 | 2018 | 249 | 0.04 | Why? |
| Acetaminophen | 1 | 2020 | 326 | 0.04 | Why? |
| History, 19th Century | 1 | 2019 | 384 | 0.04 | Why? |
| Diphtheria | 1 | 2018 | 74 | 0.04 | Why? |
| Poliovirus | 1 | 2018 | 109 | 0.04 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2018 | 91 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Serum | 1 | 2018 | 294 | 0.04 | Why? |
| Malawi | 1 | 2017 | 287 | 0.04 | Why? |
| Models, Molecular | 2 | 2021 | 7616 | 0.04 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.04 | Why? |
| Protein Structure, Tertiary | 1 | 2021 | 1565 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2019 | 511 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2021 | 1517 | 0.04 | Why? |
| Mutation Rate | 1 | 2018 | 382 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4545 | 0.04 | Why? |
| Sanitation | 1 | 2019 | 403 | 0.04 | Why? |
| 5' Untranslated Regions | 1 | 2018 | 375 | 0.04 | Why? |
| Whooping Cough | 1 | 2018 | 201 | 0.04 | Why? |
| Critical Care | 1 | 2019 | 14081 | 0.04 | Why? |
| Infant, Newborn, Diseases | 1 | 2019 | 394 | 0.04 | Why? |
| Fetal Growth Retardation | 1 | 2017 | 217 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.03 | Why? |
| Adenoviridae | 1 | 2021 | 1151 | 0.03 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.03 | Why? |
| Maternal Health | 1 | 2019 | 331 | 0.03 | Why? |
| Stillbirth | 1 | 2019 | 544 | 0.03 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.03 | Why? |
| Structure-Activity Relationship | 1 | 2021 | 2219 | 0.03 | Why? |
| Fatal Outcome | 1 | 2004 | 3438 | 0.03 | Why? |
| Poliomyelitis | 1 | 2018 | 263 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2021 | 2689 | 0.03 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2021 | 2739 | 0.03 | Why? |
| Cell Proliferation | 1 | 2021 | 1973 | 0.03 | Why? |
| Pediatricians | 1 | 2018 | 401 | 0.03 | Why? |
| Safety | 1 | 2021 | 1583 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2019 | 11559 | 0.03 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.03 | Why? |
| Bronchodilator Agents | 1 | 2018 | 444 | 0.03 | Why? |
| Hygiene | 1 | 2019 | 987 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2020 | 9091 | 0.03 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Attitude | 1 | 2020 | 1481 | 0.03 | Why? |
| Nasal Mucosa | 1 | 2018 | 1218 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.03 | Why? |
| Public Opinion | 1 | 2020 | 1165 | 0.03 | Why? |
| Patient Acceptance of Health Care | 2 | 2021 | 5002 | 0.03 | Why? |
| Pakistan | 1 | 2018 | 2302 | 0.03 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Congresses as Topic | 1 | 2019 | 1347 | 0.02 | Why? |
| Drug Approval | 1 | 2019 | 1325 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.02 | Why? |
| Resource Allocation | 1 | 2021 | 1771 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.02 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Tuberculosis | 1 | 2004 | 2895 | 0.02 | Why? |
| Poverty | 1 | 2019 | 2302 | 0.02 | Why? |
| Prognosis | 1 | 2011 | 32490 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Premature Birth | 1 | 2019 | 2151 | 0.02 | Why? |
| Health Services Accessibility | 2 | 2021 | 10697 | 0.02 | Why? |
| Genomics | 1 | 2019 | 3118 | 0.02 | Why? |
| Decision Making | 1 | 2021 | 3132 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2018 | 43792 | 0.02 | Why? |
| Risk Factors | 1 | 2014 | 71621 | 0.02 | Why? |
| Developing Countries | 1 | 2019 | 4283 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2020 | 10998 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 13720 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2019 | 29620 | 0.01 | Why? |